The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia.

Abstract

Quality of life (QOL) was assessed in 10 patients receiving treatment with recombinant methionyl human granulocyte colony-stimulating factor (r-met-GCSF). The Ferrans & Powers Quality of Life Index (Cancer II) was administered at three different time points to patients with severe chronic neutropenia. Mean overall QOL increased from time 1 to time 2 from a score of 23.72 to a score of 35.93 (p = 0.006). Overall QOL was maintained throughout the study with a mean score at time 3 of 36.96 (p = 0.002). Measures on all QOL subscales, including health and functioning and socioeconomic, improved significantly. Daily therapy with r-met-GCSF significantly improves the QOL of patients with severe chronic neutropenia.

• Authors: M T Fazio, J A Glaspy
• Journal: Oncology nursing forum (Oncol Nurs Forum) 1991 Nov-Dec Vol. 18 Issue 8 Pg. 1411-4 ISSN: 0190-535X [Print] United States
• PMID: 1722310 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor

Topics

• Adolescent
• Adult
• Child
• Child, Preschool
• Chronic Disease
• Female
• Granulocyte Colony-Stimulating Factor (therapeutic use)
• Humans
• Infant
• Male
• Neutropenia (congenital, psychology, therapy)
• Quality of Life
• Recombinant Proteins